glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) It has proven to result in significant reductions in A1c levels and body weight. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company’s (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Mounjaro™ is the newest in the class of GLP-1 analogues. Mounjaro (tirzepatide) is a prescription injection used to manage blood sugar levels in adults with type 2 diabetes.